TrialNature communications2022

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma.

Lingfang Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.